Drug details

Vyndaqel and Vyndamax (tafamidis and tafamidis meglumine capsules)

type of Cardiovascular, Other

Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• rash,
• itching, and
• severe dizziness

The following drugs are related to Vyndaqel and Vyndamax, either as a replacement or used together:

• Accupril (quinapril hydrochloride)
• Aceon (perindopril erbumine)
• Altace (ramipril tablets)
• Altace Capsules (ramipril capsules)
• Amvuttra (vutrisiran injection)
• Atacand (candesartan cilexetil)
• Atacand HCT (candesartan cilexetil-hydrochlorothiazide)
• Capoten (captopril)
• Cozaar (losartan potassium)
• Diovan (valsartan)
• Diovan HCT (valsartan and hydrochlorothiazide)
• Vasotec (enalapril)
• Monopril (fosinopril sodium)
• Monopril HCT (fosinopril sodium-hydrochlorothiazide tablets)
• Prinivil (lisinopril)
• Zestril (lisinopril)
• Mavik (trandolapril)